Furthermore, unlike receptor-focused GIPR antagonists, HCR-188 binds circulating GIP ligand, which is expressed exclusively by K cells in the small intestine. In contrast, GIPR is expressed ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

It works by activating receptors of the GLP-1 hormone while blocking receptors of the GIP hormone. Meanwhile, Eli Lilly and Company’s weight-loss drug Zepbound activates both receptors.

Eli Lilly’s weight loss blockbuster Zepbound activates both the GIP and GLP-1 receptors, while Versant-backed Pep2Tango has a tetra-receptor agonist peptide targeting GIP among its pipeline.

Users of weight-loss medications like Ozempic and Tirzepatide are going blind, according to a new study. The study, published in JAMA Opthalmology, reports multiple cases of serious eye complications ...

Furthermore, unlike receptor-focused GIPR antagonists, HCR-188 binds circulating GIP ligand, which is expressed exclusively by K cells in the small intestine. In contrast, GIPR is expressed throughout ...